The pathogenesis of multiple sclerosis: is it really a primary inflammatory process?

Ferguson B , Matyszak MK , Esiri MM , Perry VH. Axonal damage in acute multiple sclerosis lesions . Brain 1997; 120: 393-399 .

Trapp BD , Peterson J , Ransohoff RM , Rudick R , Mörk S , Bö L. Axonal transection in the lesions of multiple sclerosis . N Engl J Med 1998; 338: 278-285 .

Bitsch A , Schuchardt J , Bunkowski S , Kuhlmann T , Brück W. Acute axonal injury in multiple sclerosis correlation with demyelination and inflammation . Brain 2000; 123: 1174-1183 .

De Stefano N , Narayanan S , Francis GS , Arnaoutelis R , Tartaglia MC , Antel JP et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability . Arch Neurol 2001; 58: 65-70 .

Ingle GT , Stevenson VL , Miller DH , Thompson AJ. Primary progressive multiple sclerosis: a 5-year clinical and MR study . Brain 2003; 126: 2528-2536 .

Griffin CM , Dehmeshki J , Chard DT , Parker GJ , Barker GJ , Thompson AJ et al. T1 histograms of normal-appearing brain tissue are abnormal in early relapsing-remitting multiple sclerosis . Mult Scler 2002; 8: 211-216 .

Brex PA , Leary SM , O’Riordan JI , Miszkiel KA , Plant GT , Thompson AJ et al. Measurement of spinal cord area in clinically isolated syndromes suggestive of multiple sclerosis . J Neurol Neurosurg Psych 2001; 70: 544-547 .

Dalton CM , Brex PA , Jenkins R , Fox NC , Miszkiel KA , Crum WR et al. Progressive ventricular enlargement in patients with clinically isolated syndromes is associated with the early development of multiple sclerosis . J Neurol Neurosurg Psych 2002; 73: 141-147 .

Rocca MA , Mezzapesa DM , Falini A , Ghezzi A , Martinelli V , Scotti G et al. Evidence for axonal pathology and adaptive cortical reorganization in patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis . Neuroimage 2003; 18: 847-855 .

Neumann H. The immunological microenvironment in the CNS: implications on neuronal cell death and survival . J Neural Transm 2000; S59: 59-68 .

Streit WJ , Graeber MB , Kreutzberg GW. Peripheral nerve lesion produces increased levels of major histocompatibility complex antigens in the central nervous system . J Neuroimmunol 1989; 21: 117-123 .

Moalem G , Leibowitz-Amit R , Yoles E , Mor F , Cohen IR , Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy . Nature Med 1999; 5: 49-55 .

Serpe CJ , Sanders VM , Jones KJ. Kinetics of facial motor-neuron loss following facial nerve transection in severe combined immunodeficient mice . J Neurosci Res 2000; 62: 273-278 .

Rapalino O , Lazarov-Spiegler O , Agranov E , Velan GJ , Yoles E , Friadakis M et al. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats . Nature Med 1998; 4: 814-821 .

Yan Q , Elliott J , Snider WD. Brain-derived neurotrophic factor rescues spinal motor neurons from axotomy-induced cell death . Nature 1992; 360: 753-755 .

Gravel C , Götz R , Lorrain A , Sendtner M. Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons . Nature Med 1997; 3: 765-769 .

Ebers GC. Natural history of multiple sclerosis . J Neurol Neurosurg Psych 2001; 71: II16-II19 .

Confavreux C , Vukusic S , Moreau T , Adeleine P. Relapses and progression of disability in multiple sclerosis . N Engl J Med 2000; 343: 1430-1438 .

Kremenchutzky M , Cottrell D , Rice G , Hader W , Baskerville J , Koopman W , Ebers GC. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation . Brain 1999; 122: 1941-1950 .

Thompson AJ , Kermode AG , Wicks D , MacManus DG , Kendall BE , Kingsley PE et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis . Ann Neurol 1991; 29: 53-62 .

de Jong BA , Schrijver HM , Huizinga TWJ , Bollen ELEM , Polman CH , Uitdehaag BMJ et al. Innate production of interleukin-10 and tumor necrosis factor affects the risk of multiple sclerosis . Ann Neurol 2000; 48: 641-646 .

The IFNB Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology 1993; 43: 655-661 .

The Multiple Sclerosis Collaborative Research Group (MSCRG) . Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis . Ann Neurol 1996; 39: 285-294 .

PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group . Randomised double-blind placebo-controlled study of inter-feron beta-1a in relapsing/remitting multiple sclerosis . Lancet 1998; 352: 1498-1504 .

The Copolymer 1 Multiple Sclerosis Study Group . Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial . Neurology 1995; 45: 1268-1276 .

European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis . Lancet 1998; 352: 1491-1497 .

North American Study Group . Interferon beta-1b in secondary progressive MS: clinical and MRI results of a 3-year randomised controlled trial . American Academy of Neurology 2000; (abstract).

Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group . Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results . Neurology 2001; 56: 1496-1504 .

Liu C , Blumhardt LD. Disability outcome measures in therapeutic trials of relapsing -remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts . J Neurol Neurosurg Psych 2000; 68: 450-457 .

Karlik S , Kirk S , Nicolle E , Kremenchutzky M , Rice GPA. Evidence for very long term efficacy of interferon beta 1b in relapsing remitting MS patients . Mult Scler Clin Lab Res 2001; 7: S52-S52 .

Rice GPA , Nicolle E , Lesaux J , Ebers GC , Kremenchutzky M , Karlik S. Long term safety, compliance and evolution of neutralizing antibodies in MS patients treated with interferon beta 1B . Mult Scler Clin Lab Res 2001; 7: S54-S54 .

Li DK , Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta-1a in relapsing -remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta-1a Subcutaneously in Multiple Sclerosis . Ann Neurol 1999; 46: 197-206 .

European Study Group on Interferon beta-1b in Secondary Progressive Mutiple Sclerosis . The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis . Brain 2000; 123: 2256-2263 .

Comi G , Filippi M , Wolinsky JS. European/Canadian multi-center, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group . Ann Neurol 2001; 49: 290-297 .

Multiple Sclerosis Collaborative Research Group . Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS . Neurology 1999; 53: 1698-1704 .

Parry A , Corkill R , Blamire A , Palace J , Narayanan S , Arnold D et al. Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis . J Neurol 2003; 250: 171-178 .

Moreau T , Coles A , Wing M , Thorpe J , Miller D , Moseley I et al. CAMPATH-IH in multiple sclerosis . Mult Scler 1996; 1: 357-365 .

Coles AJ , Wing MG , Molyneux P , Paolillo A , Davie CM , Hale G et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis . Ann Neurol 1999; 46: 296-304 .

Paolillo A , Coles AJ , Molyneux PD , Gawne-Cain M , MacManus D , Barker GJ et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H . Neurology 1999; 53: 751-757 .

Lucchinetti C , Brück W , Parisi J , Scheithauer B , Rodriguez M , Lassmann H. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases . Brain 1999; 122: 2279-2295 .